Inventprise
Inventprise develops innovative vaccines against infectious diseases, focusing initially on invasive pneumococcal disease, utilizing its proprietary platform technology.
Founders
Inventprise was founded by Subhash Kapre, PhD, in 2012. The goal was to advance novel, highly impactful vaccines using proprietary technology. Since its inception, the company has focused on providing lifesaving interventions on a global scale.
Platform Technologies
Inventprise leverages its innovative platform technology to develop vaccines against infectious diseases. The company utilizes a Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker designed to create highly immunogenic and broad-spectrum conjugate vaccines. This technology enables high valency vaccines that induce broad, robust, and durable protection against pathogenic strains.
Products and Pipeline
Inventprise has a robust pipeline of investigational vaccines. The lead candidate, IVT PCV-25, is a 25-valent pneumococcal conjugate vaccine leveraging a proprietary Linker Conjugation Platform for longer-lasting and broader immune response. Other candidates include vaccines to prevent Group B Streptococcus (GBS), Shigella, and Klebsiella. IVT GBS-06, aimed at maternal immunization, is a novel hexavalent conjugate vaccine for GBS.
Manufacturing Facilities
Inventprise operates state-of-the-art, highly automated manufacturing facilities in the Redmond and Woodinville areas of Washington. These facilities support product development to large-scale cGMP commercial manufacturing. The Woodinville facility, opened in May 2022, was supported by a grant from the Bill & Melinda Gates Foundation.
Employee Programs
Inventprise offers a range of workplace programs to support employee well-being and growth. These include competitive healthcare plans, 401(k) plans, financial planning, paid time off, and holiday pay. These initiatives contribute to a supportive and engaging work environment.